✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
SUVN-G3031 is an investigational drug.
There have been 8 clinical trials for SUVN-G3031. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2022.
The most common disease conditions in clinical trials are Cognition Disorders, Depressive Disorder, Major, and Depressive Disorder. The leading clinical trial sponsors are Suven Life Sciences Limited and [disabled in preview].
There are three US patents protecting this investigational drug and eighty-five international patents.
Recent Clinical Trials for SUVN-G3031
|Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type||Suven Life Sciences Limited||Phase 3|
|A Study to Evaluate Safety, and Efficacy of SUVN-G3031 in Patients With Narcolepsy With and Without Cataplexy||Suven Life Sciences Limited||Phase 2|
|Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-911 in Healthy Subjects||Suven Life Sciences Limited||Phase 1|
Top disease conditions for SUVN-G3031
Top clinical trial sponsors for SUVN-G3031
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|SUVN-G3031||See Plans and Pricing||Combination of histamine-3 receptor inverse agonists with acetylcholinesterase inhibitors||See Plans and Pricing|
|SUVN-G3031||See Plans and Pricing||Compounds as histamine H3 receptor ligands||Suven Life Sciences Limited (Hyderabad, IN)||See Plans and Pricing|
|SUVN-G3031||See Plans and Pricing||Process for large scale production of N-[4-(1-cyclobutyl piperidin-4-yloxy) phenyl]-2-(morpholin-4-yl) acetamide dihydrochloride||Suven Life Sciences Limited (Hyderabad, IN)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|SUVN-G3031||Australia||AU2017313427||2036-08-18||See Plans and Pricing|
|SUVN-G3031||Brazil||BR112019002645||2036-08-18||See Plans and Pricing|
|SUVN-G3031||Canada||CA3033039||2036-08-18||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|